Literature DB >> 7738666

Tumor pretargeting: almost the bottom line.

D A Goodwin.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7738666

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  8 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

2.  Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

Authors:  David M Goldenberg; Chien-Hsing Chang; Robert M Sharkey; Edmund A Rossi; Habibe Karacay; William McBride; Hans J Hansen; Jean-Francois Chatal; Jacques Barbet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-06       Impact factor: 9.236

3.  Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue.

Authors:  Guozheng Liu; Shuping Dou; George Mardirossian; Jiang He; Surong Zhang; Xinrong Liu; Mary Rusckowski; Donald J Hnatowich
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

4.  Targeted radionuclide therapy.

Authors:  Lawrence E Williams; Gerald L DeNardo; Ruby F Meredith
Journal:  Med Phys       Date:  2008-07       Impact factor: 4.071

Review 5.  A semiempirical model of tumor pretargeting.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

6.  Rules of thumb for maximum percent tumor accumulation.

Authors:  Guozheng Liu
Journal:  Nucl Med Biol       Date:  2013-06-18       Impact factor: 2.408

7.  Evaluation of a Pretargeting Strategy for Molecular Imaging of the Prostate Stem Cell Antigen with a Single Chain Antibody.

Authors:  Lena Tienken; Natascha Drude; Isabell Schau; Oliver H Winz; Achim Temme; Elmar Weinhold; Felix M Mottaghy; Agnieszka Morgenroth
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

8.  Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity.

Authors:  M Chinol; P Casalini; M Maggiolo; S Canevari; E S Omodeo; P Caliceti; F M Veronese; M Cremonesi; F Chiolerio; E Nardone; A G Siccardi; G Paganelli
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.